Mergers and Acquisitions in the IVD Market

   Single User - $995
   Site License (one location, 10 users) - $1,495
   Corporate License - $1,990

Published Mar 27, 2018 | 85 Pages | Pub ID: KLI15643712

Mergers and Acquisitions in the IVD Market

As a means to more effectively address competitive pressures by capitalizing on economics of scale and scope, the in vitro diagnostics (IVD) industry continues to experience consolidations. Many of these transactions occur cross-border, particularly with U.S. and European companies seeking to enter Asia. Many also involve the acquisition of specific product lines or business units, rather than entire corporations. Kalorama Information looks at market transactions in Mergers and Acquisitions in the IVD Market, recording over 220 acquisitions in the diagnostics industry from 2015 to March 2018.

Several of the newer technologies and trends in the IVD market are helping to drive acquisitions, often bringing acquiring companies into market segments or approaches to market segments that are new and innovative. Examples of market segments or approaches to market segments in which there have been significant acquisitions include the following:
  • Gene Editing
  • Liquid Biopsy
  • Microbiome
  • Next-Generation Sequencing
  • Automation, and the Introduction of New, Large, Automated Platforms
  • Rapid Point-of-Care Testing with Single Pathogen Infectious Disease Tests
  • Connectivity
  • Looking to the East
Market leaders are not surprisingly often at the forefront of mergers and acquisitions (M&A) activities within the IVD market. Top tier IVD companies who have been active in mergers and acquisitions include:
  • Roche
  • Abbott/Alere
  • Siemens
  • Beckman Coulter, Inc. / Danaher
Among the specific acquisitions discussed in the report are:
  • Abbott's acquisition of Alere and related divestures
  • Bio-Rad's acquisition of ddPCR developer RainDance
  • Konica Minolta's entry into the health and life sciences space with the acquisition of Ambry Genetics
  • Danaher’s acquisition of molecular diagnostics leader Cepheid
The U.S. tax legislation passed in December 2017 is expected to support increased M&A activity through significantly lower corporate taxes that will provide capital for deals. This, combined with continued low interest rates and opportunities for increasing profits and/or revenues through M&A, will support M&A activity moving forward.

The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.